Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose stem cell therapy - Anterogen

Drug Profile

Adipose stem cell therapy - Anterogen

Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; Queencell

Latest Information Update: 30 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anterogen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rectal fistula; Scars; Subcutaneous fat disorders
  • Phase III Diabetic foot ulcer
  • Phase I/II Tendon injuries
  • No development reported Burns; Chronic wounds; Crohn's disease; Epidermolysis bullosa; IgA nephropathy; Osteoarthritis

Most Recent Events

  • 30 Nov 2018 NCT03754465 - added study in KDM , profile review for diabetic foot ulcer, added dev line, verified drug properties
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Epidermolysis-bullosa in South Korea (Injection)
  • 01 Nov 2018 Phase-II clinical trials in Diabetic foot ulcer in USA (unspecified route) (NCT03754465)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top